Affiliation:
1. Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
2. Department of Neurology, Qingdao Municipal Hospital, Dalian Medical University, Dalian, China
Abstract
Background: The APOE genotype has emerged as the major genetic factor for AD but differs among different alleles. Objective: To investigate the discrepant effects of APOE genotype on AD cerebrospinal fluid (CSF) biomarkers. Methods: A total of 989 non-demented ADNI participants were included. The associations of APOE ɛ2 and APOE ɛ4 with CSF biomarkers were investigated using linear regression models. Interaction and subgroup analyses were used to investigate the effects of sex and age on these associations. Furthermore, we used mediation analyses to assess whether Aβ mediated the associations between APOE genotypes and tau. Results: APOE ɛ2 carriers only showed higher Aβ levels (β [95% CI] = 0.07 [0.01, 0.13], p = 0.026). Conversely, APOE ɛ4 carriers exhibited lower Aβ concentration (β [95% CI] = –0.27 [–0.31, –0.24], p < 0.001), higher t-Tau (β [95% CI] = 0.25 [0.08, 0.18], p < 0.001) and higher p-Tau (β [95% CI] = 0.31 [0.25, 0.37], p < 0.001). Subgroup analysis showed that APOE ɛ2 was significantly positively associated with Aβ only in females (β [95% CI] = 0.12 [0.04, 0.21], p = 0.005) and older people (β [95% CI] = 0.06 [0.001, 0.12], p = 0.048). But the effects of APOE ɛ4 were independent of gender and age. Besides, the associations of APOE ɛ4 with t-Tau and p-Tau were both mediated by baseline Aβ. Conclusions: Our data suggested that APOE ɛ2 could promote Aβ clearance, while the process could be modified by sex and age. However, APOE ɛ4 might cause the accumulation of Aβ and tau pathology independent of sex and age.
Subject
Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience
Reference58 articles.
1. A quarter century of APOE and Alzheimer’s disease: Progress to date and the path forward;Belloy;Neuron,2019
2. Age, sex, and APOE ɛ4 effects on memory, brain structure, and β-amyloid across the adult life span;Jack;JAMA Neurol,2015
3. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis;Jansen;JAMA,2015
4. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy;Liu;Nat Rev Neurol,2013
5. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease;Reiman;Proc Natl Acad Sci U S A,2009